TAIPEI

台北

,

，

March 10, 2025

2025年3月10日

/PRNewswire/ -- TCI Biotech (TCI Co., Ltd.) (TWSE: 8436), a leading CDMO+ innovator in health food and skincare biotechnology, has released its consolidated financial results for the fiscal year ending

/PRNewswire/ -- TCI生物技术公司（TCI Co., Ltd.）（台证所：8436），健康食品和护肤品生物技术领域领先的CDMO+创新者，发布了其截至财年的合并财务业绩

December 31, 2024

2024年12月31日

. The company reported steady revenue performance, strong profitability, and continued investment in innovation to drive future growth.

公司报告称，收入表现稳定，盈利能力强劲，并持续投资于创新以推动未来增长。

Executive Commentary

高管评论

'Our 2024 financial performance underscores TCI Biotech's resilience and ability to navigate market fluctuations while maintaining strong profitability,' said

“我们2024年的财务表现突显了TCI生物技术公司的韧性和在市场波动中保持强劲盈利能力的能力，”

Vincent Lin

林文森

, CEO of TCI Biotech. 'We remain committed to expanding smart manufacturing, fostering strategic partnerships, and driving cutting-edge research. By strengthening our financial position, we aim to deliver sustainable growth and long-term value for our stakeholders.'

TCI生物技术公司的首席执行官表示：“我们仍然致力于扩大智能制造业，促进战略伙伴关系，并推动尖端研究。通过加强我们的财务状况，我们旨在为利益相关者提供可持续的增长和长期价值。”

Financial Highlights

财务亮点

Revenue:

收入：

NT$7.24 billion

72.4亿新台币

in 2024

2024年

Gross Profit:

毛利润：

NT$3.18 billion

31.8亿新台币

, representing a gross margin of 44%

，毛利率为44%

Operating Profit:

营业利润：

NT$1.03 billion

10.3亿新台币

, maintaining a stable 14% operating margin

，保持稳定的14%营业利润率

Net Profit:

净利润：

NT$974 million

新台币9亿7400万元

, with earnings per share (EPS) of

，每股收益（EPS）为

NT$7.60

新台币7.60元

Dividend:

股息：

NT$10

新台币10元

per share, reflecting solid financial performance

每股，反映坚实的财务表现

Cash and Cash Equivalents:

现金及现金等价物：

NT$4.77 billion

47.7亿新台币

, ensuring strong liquidity

，确保强大的流动性

Key Business Developments

关键业务发展

Expansion in International Markets: Sales growth in key regions, including

国际市场的扩张：包括关键区域的销售增长，

North America

北美

,

，

Europe

欧洲

,

，

China

中国

and

和

Asia

亚洲

, reinforcing TCI Biotech's global footprint.

，巩固了TCI Biotech的全球足迹。

Innovation & R&D: Advances in liquid supplements and skincare, aligned with market trends. The newly established TCI Medical Consultation Panel enhances research and ensures scientific rigor.

创新与研发：液体补充剂和护肤品的进展，与市场趋势保持一致。新成立的TCI医学咨询小组加强了研究并确保科学严谨性。

Operational Efficiency: Strategic cost management and AI-enhanced production processes have contributed to maintaining profitability despite industry challenges.

运营效率：战略成本管理和人工智能增强的生产流程有助于在行业挑战中保持盈利能力。

Sustainable Growth Strategies: Continued commitment to ESG (Environmental, Social and Governance) initiatives to enhance corporate responsibility and long-term value creation.

可持续增长战略：持续致力于ESG（环境、社会和治理）举措，以增强企业责任和创造长期价值。

Outlook for 2025

2025年展望

TCI Biotech is optimistic about its growth trajectory for 2025, focusing on balanced regional expansion, optimized production capacity, and strategic partnerships with global enterprises. With a commitment to quality, innovation, and customer-centric solutions, the company anticipates sustained momentum in revenue and profitability, reinforcing its position as a leader in biotechnology and smart manufacturing..

TCI生物科技公司对2025年的增长轨迹持乐观态度，专注于区域扩张的平衡、优化的生产能力以及与全球企业的战略合作伙伴关系。凭借对质量、创新和以客户为中心的解决方案的承诺，公司预计收入和盈利能力将持续增长，进一步巩固其在生物技术和智能制造领域的领导地位。

For more information, please visit

欲了解更多信息，请访问

www.tci-bio.com

www.tci-bio.com

.

。

About TCI Biotech

关于TCI生物技术

TCI Biotech (TCI Co., Ltd.) is a global leader in CDMO+ services, specializing in the research, development, and manufacturing of health foods and cosmetics. Committed to innovation and scientific excellence, TCI delivers high-quality, clinically backed products that empower customers worldwide.

TCI生物技术公司（TCI有限公司）是CDMO+服务的全球领导者，专注于健康食品和化妆品的研究、开发与制造。公司致力于创新和科学卓越，提供高质量、有临床依据支持的产品，为全球客户带来信心与价值。

Disclaimer: This press release contains forward-looking statements based on current expectations and assumptions, which involve risks and uncertainties. Actual results may differ due to market conditions, regulatory changes, or other unforeseen factors.

免责声明：本新闻稿包含基于当前预期和假设的前瞻性陈述，涉及风险和不确定性。由于市场状况、监管变化或其他不可预见的因素，实际结果可能有所不同。

TCI

TCI

Biotech assumes no obligation to update forward-looking statements. Investors are advised to review the full financial report and consult professional advisors before making any investment decisions.

生物技术公司不对更新前瞻性声明承担任何义务。建议投资者在做出任何投资决定之前，查阅完整的财务报告并咨询专业顾问。

SOURCE TCI; TCI Bio

来源 TCI；TCI 生物

WANT YOUR COMPANY'S NEWS

想要贵公司的新闻

FEATURED ON PRNEWSWIRE.COM?

刊登在PRNEWSWIRE.COM上？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers

影响者

9k+

9k+

Digital Media

数字媒体

Outlets

插座

270k+

27万+

Journalists

记者

Opted In

已选择加入

GET STARTED

开始使用